.jetcityimage/iStock Content through Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its own best biopharma pick for 2025 and also rated one more nine names in the space as overweight. The investment bank said in a details that it remains to feel “diabesity is readied to become.